The University of Sheffield and the charity Yorkshire Cancer Research have worked together to develop a new multi-million-pound fund, available exclusively to researchers at all career levels at the University, which will lay the foundation for ground-breaking cancer research in years to come.
In 2005, pioneering research at the University of Sheffield, funded by Yorkshire Cancer Research, successfully demonstrated how PARP inhibitors could be used as a tailored treatment for patients with BRCA mutations.
The discovery was patent-protected and licensed to KuDOS, a pharmaceutical company later acquired by AstraZeneca, who continued the development process and undertook successful clinical trials. This resulted in the development of three drugs called Lynparza, Zejula and Talzenna.
Lynparza – a PARP inhibitor also known as olaparib – became the first cancer drug targeting an inherited genetic fault to be made available on the NHS.
This work has enabled Yorkshire Cancer Research to establish two funds, ringfenced for University of Sheffield staff: the Yorkshire Cancer Research Sheffield Pioneers fund and the Yorkshire Cancer Research More Life to Live fund (included under the Yorkshire Cancer Research scheme called 'For More Life Without Cancer').
University of Sheffield researchers are funded from a range of funders, including the Medical Research Council and other UK Research & Innovation councils, charities such as Cancer Research UK and the Wellcome Trust and industrial sponsors.
Please contact the team at firstname.lastname@example.org in the first instance to find out more about available funding and opportunities.
A global reputation
Sheffield is a research university with a global reputation for excellence. We're a member of the Russell Group: one of the 24 leading UK universities for research and teaching.